(Q46733389)

24 December 2017

title

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. (English)

1 reference

24 December 2017

author name string

Nilofer S Azad

1 reference

24 December 2017

Christina M Annunziata

1 reference

24 December 2017

Seth M Steinberg

1 reference

24 December 2017

Lori Minasian

1 reference

24 December 2017

Ahalya Premkumar

1 reference

24 December 2017

Catherine Chow

1 reference

24 December 2017

Herbert L Kotz

1 reference

24 December 2017

Elise C Kohn

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

1 reference

24 December 2017

page(s)

1726-1732

1 reference

24 December 2017

CA 125: the past and the future

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

New tumor markers: CA125 and beyond.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Early serum CA125 response and outcome in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Use of CA 125 in follow-up of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23374

7 January 2021

Identifiers

DOI

10.1002/CNCR.23374

1 reference

24 December 2017

1 reference

24 December 2017